Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat phase II trial in diffuse cutaneous systemic sclerosis
NL-OMON44560Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Riociguat with Placebo (2 arms). Primary endpoint: Change in modified Rodnan skin score. Started Feb 2015; status: active, not recruiting.
02
Drugs
riociguat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NL-OMON44560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44560.